Table S1. Characteristics of control groups and HIV/HCV co-infected patients.

	Healthy blood subjects	HIV monoinfected patients	HIV/HCV coinfected patients	p-values
No.	32	39	206	-
Gender (male)	17 (53.1%)	24 (61.5%)	162 (78.6%)	**0.002**
Age (years)	49.5 (47; 53)	51 (46; 53)	49 (46; 52)	0.342
BMI (kg/m^2)	24.9 (23.1; 27.1)	25.3 (23.5; 26.6)	24.4 (21.8; 26.8)	0.236
Diabetes	-	6 (15.8%)	18 (8.7%)	0.181
Current alcohol drinker (>50 g/day)	-	1 (2.5%)	6 (2.9%)	0.891
Alcohol ex-drinker	-	0 (0%)	101 (49.3%)	**<0.001**
HIV acquired by IVDU	-	0 (0%)	160 (78.8%)	**<0.001**
Prior AIDS	-	13 (33.3%)	54 (26.6%)	0.397
Years since HIV infection	-	-	23 (18; 26)	-
Years since HCV infection	-	-	21 (17; 24)	-
Antiretroviral therapy				
Non treated	-	0 (0%)	3 (1.5%)	0.446
PI-based	-	10 (25.6%)	29 (14.3%)	0.087
2NRTI+II-based	-	4 (10.2%)	53 (26.1%)	**0.038**
2NRTI+PI-based	-	0 (0%)	42 (20.7%)	**0.003**
2NRTI+NNRTI-based	-	23 (64.1%)	64 (31.5%)	**<0.001**
Others	-	2 (5.1%)	15 (7.2%)	0.845
HIV markers				
Nadir CD4+ T-cells	-	215 (107; 343)	172 (87; 252)	**0.033**
Nadir CD4+ T-cells<200 cells/mm^3	-	14 (38.9%)	113 (58.9%)	**0.026**
CD4+ T-cells [#]	-	832 (685; 1036)	558 (394; 808)	**<0.001**
CD4+ T-cells<500 cells/mm^3	-	0 (0%)	83 (40.3%)	**<0.001**
HIV-RNA >50 cp/mL	-	0 (0%)	0 (0%)	0.999
HCV markers				
HCV genotype				
1	-	-	149 (72.7%)	-
2	-	-	5 (2.4%)	-
3	-	-	35 (16.5%)	-
4	-	-	17 (8.3%)	-
Log10 HCV-RNA (IU/ml)	-	-	6.29 (5.83; 6.71)	-
HCV-RNA > 850,000 IU/ml	-	-	144 (69.9%)	-

Statistics: Categorical variables are expressed as the absolute count (percentage). Continuous variables are expressed as the median (percentile 25; percentile 75). P-values were estimated with a nonparametric Mann-Whitney U test for continuous variables and Chi-square for categorical variables.

Abbreviations: HCV, Hepatitis C virus; HCV-RNA, HCV plasma viral load; HIV-1, Human immunodeficiency virus type 1; HIV-RNA, HIV plasma viral load; IVDU, intravenous drug user; NNRTI, non-nucleoside analogue HIV reverse transcriptase inhibitor; NRTI, nucleoside analogue HIV reverse transcriptase inhibitor; PI, protease inhibitor; II, integrase inhibitor.